• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)Chief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

出版信息

Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24.

PMID:29950953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6015237/
Abstract
摘要

相似文献

1
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)Chief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.一期特别会议回顾版：2017年美国肝病研究学会肝脏会议丙肝病毒研究亮点：2017年美国肝病研究学会肝脏会议部分报告回顾 • 2017年10月20 - 24日 • 华盛顿特区• 格卡瑞韦/哌柏瑞韦治疗慢性1 - 6型丙肝病毒感染合并代偿期肝硬化成人患者的疗效、安全性及药代动力学：一项综合分析• 接受阿片类激动剂治疗的参与者在接受艾尔巴韦/格拉瑞韦治疗后丙肝病毒再感染及注射风险行为：CO - STAR B部分• 格卡瑞韦/哌柏瑞韦治疗初治慢性丙肝基因3型患者8周或12周的疗效与安全性：一项2/3期综合分析• NS5A抑制剂经治的丙肝病毒感染患者使用索磷布韦/维帕他韦/伏西瑞韦治疗12周：3期POLARIS - 1研究中延迟治疗组的结果• 丙肝病毒感染患者对泛基因型格卡瑞韦/哌柏瑞韦治疗的依从性及SVR12：2/3期临床试验项目的综合分析• C - BREEZE 1和2研究：鲁扎斯韦联合乌普瑞司他韦治疗慢性丙肝病毒基因1、2、3、4或6型感染成人患者12周的疗效与安全性100% SVR率，使用来迪派韦/索磷布韦治疗8周，用于感染艾滋病毒的急性丙肝男性患者：SWIFT - C试验（不含干扰素的含索磷布韦方案治疗艾滋病毒1型感染个体的急性丙肝）结果肝病科主任大学移植中心医学临床教授德克萨斯大学健康科学中心圣安东尼奥分校德克萨斯州圣安东尼奥
Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24.
2
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.在未患有肝硬化且感染 HCV 基因 1、2 或 3 型的参与者中，与格拉瑞韦/艾尔巴韦/奥比他韦相比，格拉瑞韦/鲁索那韦/乌帕司他韦 8 周疗程的安全性和疗效（C-CREST-1 和 C-CREST-2，A 部分）：两项随机、2 期、开放性标签试验。
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.
3
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2015年欧洲肝脏研究学会（EASL）第50届年会丙肝病毒感染治疗进展•2015年4月22 - 26日•奥地利维也纳特别报道：• 达卡他韦、索磷布韦和利巴韦林联合治疗晚期肝硬化或移植后复发丙肝患者：3期ALLY - 1研究• 格卡瑞韦和艾尔巴韦治疗Child - Pugh B级肝硬化的丙肝基因1型感染患者的疗效和安全性（C - SALT A部分）• 来迪派韦/索磷布韦联合利巴韦林治疗失代偿期及肝移植后丙肝感染患者安全有效：前瞻性SOLAR 2试验初步结果• 基于来迪派韦/索磷布韦方案治疗8周或12周失败的患者采用来迪派韦/索磷布韦再治疗24周• 索磷布韦 + 聚乙二醇干扰素/利巴韦林治疗12周与索磷布韦 + 利巴韦林治疗16周或24周用于基因3型丙肝感染患者及有治疗经验的基因2型丙肝肝硬化患者：BOSON研究• 达卡他韦 - 索磷布韦联合治疗法国观察性队列ANRS CO22 HEPATHER中丙肝基因1型单感染患者的安全性和有效性• C - SWIFT：格卡瑞韦/艾尔巴韦 + 索磷布韦治疗初治的基因1型丙肝病毒感染的肝硬化和非肝硬化患者4、6或8周，以及基因3型感染患者8或12周加会议摘要及专家评论作者：医学博士史蒂文·L·弗拉姆西北大学费恩伯格医学院肝脏移植项目主任医学与外科学教授伊利诺伊州芝加哥市
Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23.
4
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, Spain• Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study• Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry• High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6• Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis• Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study• 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients With CirrhosisChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.一期特别会议回顾版：2016年欧洲肝脏研究学会会议上丙型肝炎病毒感染治疗进展：欧洲肝脏研究学会年会 • 2016年4月13 - 17日 • 西班牙巴塞罗那 • 索磷布韦/维帕他韦六周疗程足以治疗急性丙型肝炎病毒1型单一感染：HepNet急性丙型肝炎病毒IV研究 • 晚期肝硬化患者的丙型肝炎病毒治疗：是否始终合理？HEPA - C注册研究分析 • 索磷布韦/维帕他韦联合GS - 9857对既往接受治疗的1至6型丙型肝炎病毒患者的高效性 • 基线耐药相关变异（RAV）对来迪派韦/索磷布韦或西米普明/索磷布韦抗1型丙型肝炎病毒感染疗效的影响及流行情况：HCV - TARGET中期分析 • 索磷布韦/维帕他韦治疗丙型肝炎病毒和HIV - 1合并感染患者12周：ASTRAL - 5研究 • 初治的丙型肝炎病毒3型感染肝硬化患者使用ABT - 493和ABT - 530联合或不联合利巴韦林治疗，持续病毒学应答率达100% 肝脏移植项目主任 医学与外科学教授 西北大学费恩伯格医学院 伊利诺伊州芝加哥
Gastroenterol Hepatol (N Y). 2016 Jun;12(6 Suppl 2):1-22.
5
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2014年欧洲肝脏研究协会第49届年会——丙型肝炎病毒感染治疗进展•2014年4月9日至13日•英国伦敦 特别报道： • SAPPHIRE II：ABT - 450/R/ABT - 267、ABT - 333与利巴韦林组成的不含干扰素的12周方案用于治疗经验丰富的丙型肝炎病毒1型感染成人的3期安慰剂对照研究 • 索磷布韦/来迪帕司韦全口服固定剂量联合用药（含或不含利巴韦林）治疗初治1型丙型肝炎病毒感染患者12周或24周：3期ION - 1研究 • PEARL - III：ABT - 450/R/267 + ABT - 333治疗12周使419例初治丙型肝炎病毒1b型感染成人（无论是否使用利巴韦林）的持续病毒学应答率超过99% • 2期研究M12 - 999结果：ABT - 450/R/ABT - 267 + ABT - 333 + 利巴韦林不含干扰素方案用于肝移植受者复发性丙型肝炎病毒1型感染 • 索磷布韦和利巴韦林治疗伴或不伴失代偿的肝硬化和门静脉高压的慢性丙型肝炎：早期病毒学应答和安全性 • 达卡他韦和阿舒瑞韦全口服双联疗法治疗丙型肝炎病毒1b型感染患者：3期研究结果 • 索磷布韦/来迪帕司韦固定剂量联合用药在包括3型患者、失代偿1型患者和有索磷布韦治疗史的1型患者等难治人群中安全有效 • 索磷布韦和利巴韦林治疗肝移植后复发性丙型肝炎感染：一项前瞻性多中心研究结果 加会议摘要总结及专家评论： 医学博士史蒂文·L·弗拉姆（Steven L. Flamm） 西北大学费恩伯格医学院肝脏移植项目主任 医学与外科学教授 伊利诺伊州芝加哥市
Gastroenterol Hepatol (N Y). 2014 Jun;10(6 Suppl 2):1-19.
6
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.固定剂量组合方案格拉瑞韦、鲁索那韦和奥比福韦酯联合或不联合利巴韦林治疗伴有或不伴有肝硬化的慢性丙型肝炎病毒基因型 1、2 或 3 感染患者的安全性和疗效（C-CREST-1 和 C-CREST-2，B 部分）：两项随机、2 期、开放性标签试验。
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.
7
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.格卡瑞韦/哌仑他韦治疗丙型肝炎病毒与人类免疫缺陷病毒 1 型合并感染患者的疗效和安全性：EXPEDITION-2 研究。
Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220.
8
A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York.特别会议回顾版：2014年肝脏会议丙型肝炎病毒治疗亮点：2014年肝脏会议精选报告回顾，2014年11月7日至11日，马萨诸塞州波士顿。特别报道：•TRIO网络中基于索非布韦和西米普明的治疗方案评估；•基于新型直接抗病毒药物的丙型肝炎移植后治疗的安全性和有效性：HCV-TARGET纵向观察性研究的中期结果；•MK-5172和MK-8742±利巴韦林在丙型肝炎基因1型感染的肝硬化患者或既往无应答患者中的疗效和安全性：C-WORTHY研究（A和B部分）的最终结果；•索非布韦联合西米普明+利巴韦林在基因1型患者中的安全性和有效性：一项前瞻性观察性研究的中期结果；•达卡他韦/阿舒瑞韦/BMS-791325全口服固定剂量联合治疗，±利巴韦林，用于慢性丙型肝炎基因1型感染和代偿性肝硬化患者：UNITY-2 3期SVR-12结果；•TURQUOISE-II：ABT-450/R/奥比他韦和达沙布韦联合利巴韦林方案在丙型肝炎基因1型感染的肝硬化患者中实现了高SVR12率，无论基线特征如何。另外还有会议摘要及专家评论：医学博士 Ira M. Jacobson，胃肠病学和肝病科主任，威尔康奈尔医学院医学Vincent Astor杰出教授，纽约长老会医院主治医师，纽约，纽约。
Gastroenterol Hepatol (N Y). 2014 Dec;10(12 Suppl 6):1-19.
9
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.两种直接作用抗病毒药物联合治疗方案 ruzasvir 180mg 和 uprifosbuvir 450mg 治疗慢性丙型肝炎病毒基因型 1、2、3、4、5 或 6 成人患者 12 周的疗效和安全性。
J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.
10
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.真实世界中 glecaprevir/pibrentasvir 治疗慢性丙型肝炎感染的疗效和安全性：来自德国丙型肝炎注册研究的数据。
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.

引用本文的文献

1
A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis.一例glecaprevir/pibrentasvir诱导的代偿期肝硬化患者严重高胆红素血症的病例报告。
Medicine (Baltimore). 2019 Sep;98(39):e17343. doi: 10.1097/MD.0000000000017343.

本文引用的文献

1
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.格卡瑞韦哌仑他韦联合比索那韦/利托那韦治疗代偿期肝硬化的成人慢性丙型肝炎病毒基因型 1、2、4、5 或 6 感染（EXPEDITION-1）：一项单臂、开放标签、多中心 3 期临床试验。
Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14.
2
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
3
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.6 周 Ledipasvir-索磷布韦治疗 HIV 合并感染的急性丙型肝炎病毒基因型 1 或 4 感染：一项开放标签、单臂试验。
Lancet Gastroenterol Hepatol. 2017 May;2(5):347-353. doi: 10.1016/S2468-1253(17)30003-1. Epub 2017 Mar 1.
4
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.Elbasvir/Grazoprevir 治疗丙型肝炎病毒感染伴遗传性血液疾病患者：一项 III 期研究。
Hepatology. 2017 Sep;66(3):736-745. doi: 10.1002/hep.29139. Epub 2017 Jul 20.
5
Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.下一代丙型肝炎病毒NS5A抑制剂比布伦特斯韦的抗病毒活性及耐药性概况
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02558-16. Print 2017 May.
6
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.glecaprevir和pibrentasvir治疗丙型肝炎病毒1型感染及既往直接抗病毒治疗12周。
Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10.
7
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.6 周 Ledipasvir 联合 Sofosbuvir 固定剂量复方制剂治疗急性丙型肝炎病毒基因 1 型单感染患者（HepNet Acute HCV IV）：一项开放标签、单臂、2 期研究。
Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.
8
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.Elbasvir 和 Grazoprevir 联合治疗方案，联合或不联合利巴韦林，治疗慢性丙型肝炎感染经验丰富的患者的疗效。
Gastroenterology. 2017 Jan;152(1):164-175.e4. doi: 10.1053/j.gastro.2016.09.045. Epub 2016 Oct 5.
9
EASL Recommendations on Treatment of Hepatitis C 2016.2016年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.
10
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.格拉瑞韦联合艾尔巴韦在初治和经治的丙型肝炎病毒基因型 1 感染和 4-5 期慢性肾脏病患者中的疗效（C-SURFER 研究）：一项联合 III 期研究。
Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5.